Five-Day Blister Progression in 50 Ultramarathon Runners
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: What did this specific study measure, in whom, at what timepoint—and what would go beyond its evidence?
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 50 runners in the 2010 and 2011 five-day, 219-km Al Andalus Ultimate Trail. |
| Design | Prospective field cohort with daily post-race interviews on blister occurrence, site, pain and preventive measures. |
| Comparator | Blister prevalence was compared across race stages and by reported preventive measures and prior ultramarathon experience. |
| Timepoint | Daily through four completed stages totaling 182 km. |
| Key result | Blisters affected 34% after day one, 54% after day two, 72% after day three and 76% after day four (p<0.001 versus day one). Sixty-five percent formed on toes. Socks, powders, lubricants, antiperspirants and prophylactic taping were not associated with lower rates; prior ultramarathon experience in men correlated with fewer blisters (r=-0.44, p<0.05). |
| Funding/conflict context | The PubMed abstract does not state funding or conflict disclosures. No cosmetic moisturizer was tested. |
What was actually measured?
Blisters affected 34% after day one, 54% after day two, 72% after day three and 76% after day four (p<0.001 versus day one). Sixty-five percent formed on toes. Socks, powders, lubricants, antiperspirants and prophylactic taping were not associated with lower rates; prior ultramarathon experience in men correlated with fewer blisters (r=-0.44, p<0.05).
Daily prospective recording captures accumulation over distance, but null findings for individual prevention choices are underpowered and confounded by self-selection.
The denominator defines the scope. A workplace outbreak, clinic series, questionnaire, case report and long-term cohort answer different questions. Their percentages and odds ratios cannot be silently transferred to another population.
What the result does not prove
Fifty runners, two editions of one event, self-selected preventive methods, multiple comparisons and no randomized intervention limit causal conclusions.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.
Exposure detail matters more than the job label
People with the same title may handle different materials for different durations. Useful documentation identifies the exact product or process, route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, chemical, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve away from work or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredients and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 25275735
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Skin-Protection Knowledge Among 142 Danish Hospital Cleaners
- Six-Month Severity Change in 799 Danish Hand-Eczema Patients
- 112 Skin Infections Across 78,720 NCAA Wrestling Exposures
- Dermatitis Findings Across California Grape, Citrus and Tomato Workers
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.